Pelage Pharmaceuticals Raises $16.75M in Series A Funding

Pelage Pharmaceuticals

Pelage Pharmaceuticals, a Los Angeles, Ca-based clinical-stage regenerative medicine company, raised $16.75M in Series A funding.

The round was led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures.

The company intends to use the funds to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.

Led by CEO Daniel Gil, Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing novel treatments for hair loss including androgenetic alopecia and chemotherapy-induced-alopecia. With a focus on molecular and stem cell biology, it is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in clinical trials.

Commenting on the news, Daniel Gil said: “We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells. With the support of GV, Main Street Advisors and other top-tier investors, we expect to advance our lead program to a Phase 2a clinical trial in the second half of this year.”